Co-Founder, Day One Biopharmaceuticals
Appears in 1 story
Retired from Day One in late 2024; joined Pediatric Brain Tumor Foundation board
For decades, children with relapsed brain tumors had no approved targeted treatment. That changed in April 2024 when the FDA cleared Ojemda, a once-weekly pill for pediatric low-grade glioma, the most common childhood brain cancer. Day One Biopharmaceuticals, the company behind it, has agreed to be acquired by France's Servier for $2.5 billion in cash—a 68% premium over its previous closing share price.
Updated May 30
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
